Kornimate/medical-research-clean huggingface dataset:
evaluation of physical therapy interventions and patient characteristics on outcomes

Conditions: Acute Stroke

Summary: data collection for this study will be done by clinicians working in inpatient rehabilitation units with persons with acute stroke. no interventions are included in this study. it is designed to capture trends in current clinical practice for persons with stroke. this data will be useful in identifying the most beneficial and effective walking treatments as well as most significant patient characteristics that impact recovery for persons acutely after stroke. all data collection will take place during the inpatient rehabilitation stay.

all persons admitted to the inpatient rehabilitation unit will be screened for inclusion. only those with a confirmed diagnosis of stroke (cva) will be included. data collection on the participants will begin at the time of admission and continue through discharge. average length of stay for persons with stroke in inpatient rehabilitation units is 21 days. some persons will stay fewer days and some will stay longer. data collection will include key information on physical therapy interventions including gait training, balance training, group therapy, manual therapy, exercise, transfer training, stairs, family training, wheelchair training, modalities, discharge planning, seated and supine exercises. other data will be collected including tone, motor control, sensation, gait endurance, falls, wounds, restraints, deep vein thrombosis, tracheostomy, feeding tubes and blood pressure. additional data collection will include age, gender, race, length of time post stroke, time in rehabilitation, functional independence measure scores, case mix group, discharge destination. in addition, physician history and physical as well as discharge summary will be collected, as will evaluation and discharge notes from therapies (physical, occupation, speech, social work). patients will not be responsible for any costs associated with this data collection.

Eligibility criteria:
inclusion criteria: * any patient with a confirmed primary diagnosis of stroke, within 6 weeks of onset, will be included. * persons will be between the ages of 16 and 80. * persons may have experienced a previous cva if they experienced a full gait recovery. exclusion criteria: * any patient with a history of stroke onset greater than 6 weeks prior to admission will not be included. * in addition, persons with bilateral cva will not be included as well as persons who were not ambulatory prior to the cva.

Keywords: acute stroke gait
hepatic mitochondrial function in sepsis

Conditions: Sepsis; Peritonitis

Summary: multi-organ failure due to sepsis is a major cause of death in critically ill patients. but the mechanisms leading to this condition are not fully understood. mitochondrial dysfunction has been shown in skeletal muscle of critically ill septic patients. liver is very important in sepsis as it is responsible of the synthesis of several inflammatory proteins. moreover hepatic failure is associated to a bad outcome. the aim of this study is to evaluate the hepatic mitochondrial function in sepsis.


Eligibility criteria:
inclusion criteria: * septic group : peritonitis patients needing surgery * non septic group : patients needing hepatic surgery exclusion criteria: * no liver biopsy performed

Keywords: sepsis peritonitis mitochondria liver
the outcome of the transobturator tape (tot) procedure

Conditions: Stress Urinary Incontinence

Summary: the aim of our study is to report the subjective and objective outcome of outside-in transobturator technique (tot) (monarc®) in long-term follow-up. this is a follow-up study concerning 191 patients operated on in turku university hospital between may 2003 and december 2004 by using tot. sui was diagnosed with a positive stress test, the urinary incontinence severity score (uiss) and the detrusor instability score (dis). after a mean of 6.5 years evaluation included a gynecological examination and a supine stress test. subjective outcome was evaluated with uiss, dis, a visual analogue scale (vas), a questionnaire of subjective evaluation of continence, euroqol-5d, eq-5d vas and short versions of iiq-7 and udi-6. objective cure was defined as negative stress test and an absence of reoperation for sui during the follow-up period.


Eligibility criteria:
inclusion criteria: * 191 patients operated on with the tot procedure between may 2003 and december 2004 at the department of obstetrics and gynecology in the turku university hospital. exclusion criteria:
brain functions in patients before and after bariatric surgery

Conditions: Adiposity

Summary: the project will specifically focus on the examination of the influence of substantial weight loss due to bariatric surgery on brain functions. our hypothesis is that substantial weight loss after bariatric surgery (bs) is also accompanied by changes in the balance of reward and inhibitory networks in diabetic subjects. therefore the investigators will conduct a functional magnetic resonance imaging (fmri) study investigating functional measures.


Eligibility criteria:
inclusion criteria: * bariatric surgery in the past or in the future * diabetes (at least before surgery) exclusion criteria: * fmri contraindications * claustrophobia
a study of tumor imaging with multispectral optoacoustic tomography

Conditions: Breast Cancer; Melanoma

Summary: participants in this study will have multispectral optoacoustic tomography/msot imaging of both breasts immediately before their ultrasound-guided breast biopsy procedure begins. after the mso imaging is completed, participation in the study will end.


Eligibility criteria:
inclusion criteria: * participant is a female or male who is 18 years of age or older. * participant must meet one of the following: * suspicious breast imaging finding detected on either mammography, ultrasound, or mri that is visible on ultrasound and therefore recommended for ultrasound-guided breast biopsy (bi-rads 4 suspicious abnormality; bi-rads 5, highly suggestive for malignancy) * no previous treatment for breast cancer * diagnosis of melanoma exclusion criteria: * life expectancy \< 3 months

Keywords: multispectral optoacoustic tomography imaging msot memorial sloan kettering cancer center 21-374
impact of respiratory physiotherapy in the management of infectious pleural effusion

Conditions: Pleural Diseases; Infection

Summary: chest physiotherapy (cp) facilitates the absorption of fluid in the pleural cavity and reduces the formation of fibrous adhesions in patients with pleural infection, allowing a faster clinical, functional and radiological improve. the aim of the study is to determine if the cp associated with conventional medical treatment (ct) improves functional sequelae secondary to pleural infectious.

this is a multicenter, prospective and randomized trial. objective: to determine if the chest physiotherapy (cp) associated with conventional medical treatment (ct) improves functional sequelae secondary to pleural infectious disease, defined as an increased of 15% in vital functional capacity (vfc). adult patients with diagnosis of pleural infection will be included and randomized into two branches: control group - only ct and interventional one - ct plus cp.

Eligibility criteria:
inclusion criteria: * diagnosis of infectious pleural effusion * failure to meet any exclusion criteria. exclusion criteria: * hemothorax. * malignant pleural effusion. * severe comorbidities (end-stage disease, neuromuscular diseases, etc) * previous ribcage and/or diaphragmatic pathology. * pregnancy. * previous respiratory rehabilitation program completed. * prior pleural pathology

Keywords: pleural disease infection chest physiotherapy
scrt(short course radiotherapy) combined with capox plus ql1706 for rectal cancer liver metastases

Conditions: Locally Advanced Rectal Cancer With Liver Metastases

Summary: to enhance the treatment efficacy of rectal cancer liver metastasis through a multidisciplinary approach of radiotherapy, immunotherapy, and chemotherapy, and to provide a new direction for the combination treatment strategy.


Eligibility criteria:
inclusion criteria: 1. age 18-75 years, any gender. 2. pathologically confirmed rectal cancer with liver metastases (stage m1). 3. karnofsky performance status ≥70. 4. adequate organ function, no contraindications to radiotherapy, or immunotherapy. 5. microsatellite/mismatch repair status mss/pmmr. 6. no prior chemotherapy or any other anti-tumor treatment before inclusion. 7. no prior immunotherapy. 8. ability to comply with the study protocol during the study period. 9. signed written informed consent. exclusion criteria: 1. pregnant or lactating women. 2. pathological diagnosis of signet ring cell carcinoma. 3. history of other malignancies within the past 5 years, except cured skin cancer and cervical carcinoma in situ. 4. uncontrolled epilepsy, central nervous system disorders, or history of psychiatric disorders that, in the opinion of the investigator, may interfere with signing the informed consent form or affect patient compliance with oral medication. 5. clinically significant (i.e., active) cardiac disease, such as symptomatic coronary artery disease, new york heart association (nyha) class ii or greater congestive heart failure, or significant arrhythmias requiring drug intervention (see appendix 12), or history of myocardial infarction within the past 12 months. 6. organ transplant recipients requiring immunosuppressive therapy and long-term steroid users. 7. patients with autoimmune diseases. 8. severe uncontrolled recurrent infections or other severe uncontrolled comorbidities. 9. subjects with baseline hematological and biochemical parameters not meeting the following criteria: hemoglobin ≥90g/l; absolute neutrophil count (anc) .≥1.5×10\^9/l; platelets ≥100×10\^9/l; alt, ast ≤2.5 times the upper limit of normal; alp ≤2.5 times the upper limit of normal; serum total bilirubin \<1.5 times the upper limit of normal; serum creatinine \<1 times the upper limit of normal; serum albumin ≥30g/l. 10. known deficiency of dihydropyrimidine dehydrogenase (dpd). 11. allergy to any investigational drug components.

Keywords: short course radiotheraphy capox ql1706 (bifunctional pd1/ctla4 dual blocker)
comparison of high dose and low dose dexamethasone in preventing post-extubation airway obstruction in adults

Conditions: Airway Obstruction

Summary: the specific objectives were to determine whether high dose dexamethasone are more effective than low dose dexamethasone in the reduction or prevention of post-extubation airway obstruction among patients with a cuff leak volume (clv) \< 110 ml.

controversy currently exists regarding the effectiveness of prophylactic steroid therapy for patients considered at high risk for post-extubation stridor. studies regarding the efficacy of prophylactic corticosteroids for intubated patients have yielded conflicting results due to differences in the number, dose, or type of corticosteroids administered. only a limited number of prospective trials involving adults and evaluating the benefits and the dose of corticosteroid therapy prior to extubation have been conducted.the present study was conducted to evaluate the effects of prophylactic dexamethasone therapy for a subset of high-risk patients who had been intubated for \> 48 hours and who were undergoing their first elective extubation in an icu setting.

Eligibility criteria:
inclusion criteria: all patients were \> 18 years of age and met the following weaning criteria: 1. temperature ≤ 38°c for \> 8 hours, 2. discontinuous use of sedatives, 3. heart rate ≥ 70 and ≤ 130 /min, 4. systolic blood pressure (sbp) ≥ 80 mm hg in the absence of vasopressors, 5. fraction of inspired oxygen (fio2) ≤ 0.6, pao2 ≥ 60, and partial pressure of oxygen (pao2)/fio2 ratio \> 200, 6. positive end-expiratory pressure (peep) ≤ 5 cm h2o, 7. rapid and shallow ratio of frequency to tidal volume (f/vt ≤ 105), 8. minute ventilation ≤ 15 l/min, and 9. ph ≥ 7.3. supplemental oxygen was continued to maintain an oxygen saturation \> 95% as measured by a pulse oximeter. exclusion criteria: 1. a history of extubation during the same hospitalization 2. administration of corticosteroids seven days prior to extubation.

Keywords: endotracheal intubation laryngeal edema cuff-leak test corticosteroids this study was to ascertain whether administration of dexamethasone to critically intubated patients prevent postextubation airway obstruction. this study was to compare high dose and low dose dexamethasone in preventing noninvasive ventilation or reintubation among critically ill intubated patients
use of probiotic lactobacilli for the treatment of lactational mastitis

Conditions: Mastitis

Summary: a total of 300 women with lactational infectious mastitis will daily ingest 9 log10 cfu of lactobacillus salivarius hn6, lactobacillus reuteri cr20 or lactobacillus fermentum lc40 for 4 weeks. the three lactobacilli strains were originally isolated from milk of healthy women. on days 0 and 28, milk samples will be collected, and staphylococci/streptococci and lactobacilli will be counted and identified. evolution of clinical signs will be recorded by midwifes on days 0, 7, 14 and 28.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of mastitis * staphylococcal and/or streptococcal count higher than 3000 colony-forming units per ml of milk * milk leukocyte count higher 6 log10/ml * must be able to provide a milk sample without the aid of a milk pump exclusion criteria: * mammary abscesses * any kind of parallel disease

Keywords: mastitis staphylococcus streptococcus lactation breastfeeding
efficacy and tolerability of an antiretroviral bi-therapy in hiv infected patients with multidrug resistance

Conditions: HIV Infections

Summary: this study investigated whether a calibrated reduction in antiretroviral drug pressures could stabilize the evolution and the pathogenic potential of resistant hiv viruses.

in patients with hiv multidrug resistance, maintaining a failing full-dose haart regimen usually results in significant drug toxicity and in continued accumulation of resistance mutations that can preclude future therapeutic options. in contrast, treatment interruption provokes the reemergence of wild-type virus with full replicative and pathogenic capacity. the researchers investigated whether a calibrated reduction in drug pressure could stabilize the evolution and the pathogenic potential of resistant virus. a prospective pilot study was conducted in patients receiving protease inhibitor-based haart with a resistance genotype predicting less than two active drugs according to the 2002 anrs algorithm, cd4 counts over or equal to 100/mm3 and plasma hiv rna below or equal to 5 log/ml. the treatment was low-dose idv/rtv (200/100 bid) and 3tc 150mg bid. idv doses were adjusted at week 4 to ensure a cmin of 250+/-100ng/ml, which, based on a panel of multi-pi resistant viruses, was calculated to yield an inhibitory quotient (cmin/ic50) of 0.50. primary end-points were over 25% decrease in cd4 counts (immunological failure-if), or over 0.7 log increase in plasma hiv rna (virological failure-vf) at two consecutive monthly visits during the 24-week study. inclusions were to stop when the total number of failures (vf+if) reached 7

Eligibility criteria:
inclusion criteria: * hiv-1 infection confirmed by western blot * karnofsky score over or equal to 70 * cd4 over or equal to 200/mm3 * plasma viral rna over or equal to 10 000 copies/ml and below 100 000 copies/ml. * stability of plasma viral load and cd4-during the last 3 months * failure of two antiretroviral regimens with 2 pi and one nnrti * new efficacy drug on genotype not available * treatment on hand with 3 antiretroviral drugs with one pi since 3 months. * written inform consent * pregnancy exclusion criteria: * hemoglobin below 8g/dl * neutrophils below 750/mm3 * asat, alat over 5n * hepatic insufficiency (prothrombin below 50%) * acute opportunistic infection * immunotherapy * treatment with active antiretroviral regimen * treatment with enzyme inductor

Keywords: treatment failure hiv infections
ectopic lipid deposition and insulin resistance in after treatment of acromegaly

Conditions: Acromegaly

Summary: this study investigates fat distribution in people with acromegaly. the investigator is also investigating the change of fat distribution before and after treatment of acromegaly. the investigator will compare the results of people with acromegaly to the results of healthy volunteers.


Eligibility criteria:
inclusion criteria: * ages 18 - 75 yr (both groups) * study subjects with active acromegaly * healthy controls exclusion criteria: * serum creatinine or alanine aminotransferase (alt) \> 2 times the upper limit of normal, metastatic cancer. * controls will be receiving no medications and have no chronic diseases, including cancer, hypertension or diabetes mellitus. * contraindications to mri imaging (both groups) like those with certain metal implants, surgical clips or pacemakers. * pregnant women
a trial investigating the safety, tolerability, availability and distribution in the body of once-weekly long-acting growth hormone (somapacitan) compared to once daily norditropin nordiflex® in adults with growth hormone deficiency

Conditions: Growth Hormone Disorder; Adult Growth Hormone Deficiency

Summary: this trial is conducted in europe. the aim of the trial is to investigate the safety, tolerability, availability and distribution in the body of once-weekly long-acting growth hormone (nnc0195-0092, somapacitan) compared to once daily norditropin nordiflex® in adults with growth hormone deficiency (ghd).


Eligibility criteria:
inclusion criteria: * adults with ghd as defined in the consensus guidelines for the diagnosis and treatment of adults with ghd * stable human growth hormone (hgh) replacement therapy for at least 3 months exclusion criteria: * participation in another clinical trial within 3 months or receipt of any investigational medicinal product within 3 months prior to randomisation * active malignant disease or malignant disease within the last 5 years with exception of fully treated local basal cell carcinoma or carcinoma in situ of cervix * proliferative retinopathy judged by retina-photo within the last year - only with concomitant diabetes * heart insufficiency, new york heart association (nyha) class above 2 * adults with ghd with poorly controlled diabetes mellitus with a glycosylated haemoglobin (hba1c) 64 mmol/mol (8.0%) and/or insulin treatment * stable pituitary replacement therapy for less than 3 months
axumin petmri imaging following focal cryo-ablation (fca)

Conditions: Prostate Cancer

Summary: this is a prospective outcomes study assessing quality of life and oncological control at pre-defined time points following focal cryo-ablation (fca). the investigator's standard of care is to perform an magentic resonance imaging (mri) and prostate biopsy two years following fca. the prostate biopsy assesses both the presence of in field and out of field disease. the role of axumin pet/mri for detecting disease following fca has not been previously examined.

the primary hypothesis of this study is that 18f-fluciclovine pet/mri imaging at two years following fca will improve sensitivity for detection of in field recurrence of significant prostate cancer defined as any gleason pattern 4 disease. the secondary hypothesis of this study is that 18f-fluciclovine pet/mri imaging at two years following fca will improve sensitivity for detection of out of field recurrence of significant prostate cancer .

Eligibility criteria:
inclusion criteria: * fca at nyu langone health performed at least two years prior to study enrollment by drs. lepor or wysock. * no prostate cancer specific treatment following fca * consented to undergo reflex mri and prostate biopsy two years following fca. exclusion criteria: * any contraindication to prostate biopsy * prior allergic reaction to 18f-fluciclovine * patient refuses mri and prostate biopsy two years following fca.

Keywords: 18f-fluciclovine pet imaging focal cryo ablation
real-world outcomes of nivolumab+ipilimumab and pembrolizumab+lenvatinib among us advanced renal cell carcinoma (arcc) patients

Conditions: Advanced Renal Cell Carcinoma (aRCC)

Summary: this observational study aims to describe demographic, clinical characteristics, treatment patterns outcomes of participants with advanced renal cell carcinoma (arcc) receiving either nivolumab + ipilimumab, or pembrolizumab + lenvatinib combination therapy


Eligibility criteria:
inclusion criteria: 1. age 18 years and older with diagnosis of advanced renal cell carcinoma (arcc) with predominantly clear-cell histology 2. received any of the following therapies in the first-line setting: 1. nivolumab + ipilimumab between 8/1/2021 and 6 months prior to data collection 2. pembrolizumab + lenvatinib between 8/1/2021and 6 months prior to data collection 3. participant had at least 6 months of follow-up from initiation of index treatment (patients who deceased prior to 6 months since index treatment initiation would still be eligible) exclusion criteria: 1. receipt of any immunotherapy or tyrosine kinase inhibitor (tki) therapy as part of a randomized controlled trial (rct) 2. participant received any systemic therapy for advanced renal cell carcinoma (arcc) prior to index therapy, including neoadjuvant or adjuvant therapy 3. any active malignancy in the 3 years prior to initiation of 1l therapy for arcc, except for locally curable cancers that have been cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix, or breast cancer, or localized prostate cancer with a gleason score ≤3+4 that has been treated more than 12 months prior to full study screening and considered to have a very low risk of recurrence.
safety and efficacy of al-15469a 0.5% / al-6515 0.3% ophthalmic suspension for treatment of bacterial conjunctivitis

Conditions: Bacterial Conjunctivitis

Summary: to assess safety and efficacy of al-15469a 0.5% /al-6515 0.3% ophthalmic suspension for treatment of bacterial conjunctivitis


Eligibility criteria:
inclusion criteria: * male and female patients of any race * 5 years of age and older at the time of the day 1 visit * with a primary clinical diagnosis of bacterial conjunctivitis. exclusion criteria: * onset of bacterial conjunctivitis (signs and symptoms) more than 4 days * presence of punctal plug or punctal occlusion * visual acuity worse than 20/80 * upper respiratory infection